Antibodies News and Research

RSS

Biogen to publish data on two-step assay for anti-JC virus antibody detection

Biogen Idec and Elan Corporation, plc today announced data has been published in the Annals of Neurology on an investigational, two-step assay to detect anti-JC virus (JCV) antibodies in human serum and plasma

26 Aug 2010

Improvement in mumps vaccine administration needed to prevent future outbreaks

Although immunity to mumps is high in the United States, mumps vaccine coverage must be maintained and improved to prevent future outbreaks, according to a new study, now available online (http://www.journals.uchicago.edu/doi/full/10.1086/655394), in the September 1, 2010 issue of The Journal of Infectious Diseases.

25 Aug 2010

CMC Biologics completes new, disposable manufacturing facility at Seattle

CMC Biologics, a Contract Manufacturing Organization with manufacturing sites in Europe and the USA, today announced the completion of a new state-of-the-art disposable manufacturing facility at its Seattle, WA site. The addition comes as part of a staged major expansion plan, which will add significant production capacity to its existing facility to accommodate a growing demand for cGMP manufacture of biopharmaceuticals.

25 Aug 2010

Study finds measurable immunity to pandemic H1N1 virus in Norway population

By autumn 2009, almost half of the population of Norway had been vaccinated against the pandemic influenza A (H1N1) virus. Many had also been infected by the virus during the summer and autumn outbreaks. The majority of those who were vaccinated or were infected are expected to have developed immunity to the virus.

25 Aug 2010

Researchers develop high-resolution technology to visualize individual virus particles

In the war against infectious disease, identifying the culprit is half the battle. Now, research professor Shaopeng Wang and his colleagues from the Biodesign Institute at Arizona State University, describe a new method for visualizing individual virus particles. Their research opens the door to a more detailed understanding of these minute pathogens, and may further the study of a broad range of micro- and nanoscale phenomena.

25 Aug 2010

EPA selects Precision Antibody to develop monoclonal antibodies for 'Crypto' intestinal parasite

Precision Antibody™ announced today its selection by the United States Environmental Protection Agency (EPA) to develop monoclonal antibodies to two species of Cryptosporidium, an intestinal parasite that has emerged over the past 20 years as one of the most common causes of waterborne illness in the United States.

24 Aug 2010

Researchers develop new instrumentation to simplify testing patients for infectious diseases

Arizona State University researchers have demonstrated a way to dramatically simplify testing patients for infectious diseases and unhealthy protein levels.New testing instrumentation developed by Antonia Garcia and John Schneider promises to make the procedure less costly and produce results in less time.

24 Aug 2010

New antisense drugs may help treat accidental infections: Study

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure-suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

23 Aug 2010

Researchers find new way to study oncogene's role in DNA repair

A key step in understanding the origins of familial breast cancer has been made by two teams of scientists at the University of California, Davis. The researchers have purified, for the first time, the protein produced by the breast cancer susceptibility gene BRCA2 and used it to study the oncogene's role in DNA repair.

23 Aug 2010

Melanoma Research Alliance announces grant to support six research programs

The Melanoma Research Alliance today announced $5.2 million in grants to support six multidisciplinary teams pursuing innovative, translational research approaches designed to benefit melanoma patients.

21 Aug 2010

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

20 Aug 2010

XOMA sells royalty interest in CIMZIA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced today that it has sold its royalty interest in CIMZIA® (certolizumab pegol) marketed by UCB S.A. for $4 million to an undisclosed buyer. The manufacture of CIMZIA is covered by a license to XOMA's Bacterial Cell Expression technology.

18 Aug 2010

USPTO grants Neogenix Oncology patent for DNAs encoding novel molecular aspects of NPC-1 antibody

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 7,763,720, with claims related to DNAs encoding the novel molecular aspects of the Company's NPC-1 antibody.

18 Aug 2010

NCI grants SBIR award to MabVax Therapeutics

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP).

18 Aug 2010

Studies provide evidence for new approach to MRSA vaccines

Two recent studies provide evidence for a new approach to vaccines to prevent infections caused by drug-resistant Staphylococcus aureus -- better known as MRSA - the leading cause of skin and soft tissue, bloodstream and lung infections in the United States. One demonstrates a way to counteract the bacteria's knack for evading the immune system. The other shows how to disrupt the germ's tissue-damaging mechanism.

17 Aug 2010

Intercell reports significant increase in second quarter revenue

Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets

17 Aug 2010

NanoSmart receives USPTO Notice of Allowance for cancer tumor targeting technology

NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.

16 Aug 2010

Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the John Wayne Cancer Institute in Santa Monica, California has opened enrollment in a Phase I clinical study with MORAb-028 in patients with advanced melanoma.

16 Aug 2010

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health. The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

16 Aug 2010

CD31 positive cells have potential for treating peripheral artery disease: Research

Isolating cells from a patient's blood or bone marrow that nourish blood vessels may be a safer and less arduous route to treatment of cardiovascular disease than obtaining rare stem cells, according to research from Emory University School of Medicine. In recent clinical trials, doctors in several countries have tested the ability of a patient's bone marrow cells to repair damage, such as heart attacks and peripheral artery disease, created by problems of blood flow.

16 Aug 2010

Antibodies News and Research

Biogen to publish data on two-step assay for anti-JC virus antibody detection

Improvement in mumps vaccine administration needed to prevent future outbreaks

CMC Biologics completes new, disposable manufacturing facility at Seattle

Study finds measurable immunity to pandemic H1N1 virus in Norway population

Researchers develop high-resolution technology to visualize individual virus particles

EPA selects Precision Antibody to develop monoclonal antibodies for 'Crypto' intestinal parasite

Researchers develop new instrumentation to simplify testing patients for infectious diseases

New antisense drugs may help treat accidental infections: Study

Researchers find new way to study oncogene's role in DNA repair

Melanoma Research Alliance announces grant to support six research programs

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

XOMA sells royalty interest in CIMZIA

USPTO grants Neogenix Oncology patent for DNAs encoding novel molecular aspects of NPC-1 antibody

NCI grants SBIR award to MabVax Therapeutics

Studies provide evidence for new approach to MRSA vaccines

Intercell reports significant increase in second quarter revenue

NanoSmart receives USPTO Notice of Allowance for cancer tumor targeting technology

Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

CD31 positive cells have potential for treating peripheral artery disease: Research

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo